Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Japanese Patients With Relapsed or Refractory Multiple Myeloma
NCT04696809Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Feb 2021; status: completed.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04696809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696809.